SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense debate as investors weigh the company's aggressive Bitcoin treasury strategy against concerns regarding shareholder dilution and broader market instability. The community remains deeply divided, with bulls pointing to the potential for significant long-term leverage, while bears and skeptics express concerns over high debt levels and the stock's recent performance relative to Bitcoin.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility driven by high short interest and retail sentiment surrounding a potential short squeeze, while investors debate the company's long-term valuation amid broader geopolitical concerns. Community discussion is focused on the tension between strong enterprise deal pipelines and technical selling pressure, with many traders closely monitoring support levels for a potential reversal.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense buzz as investors anticipate high-impact long-term efficacy data from the VELA Phase 3 trials at the upcoming American Academy of Dermatology conference. Community sentiment remains highly bullish, with many participants citing the potential for the drug to be classified as 'best-in-class' and speculating on an inevitable buyout by Big Pharma as institutional interest continues to mount.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing heightened volatility and intense community debate as investors weigh the company's multi-year share price decline against potential turnaround catalysts like the upcoming World Cup. While some traders are bracing for further downside amid tariff concerns and shifting consumer demand, others are actively accumulating shares at multi-year lows, betting that long-term brand resiliency and insider buying signal an impending recovery.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors look toward the upcoming 10-K filing and earnings report, with the community closely tracking the company's debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high despite short-interest pressure, as retail investors anticipate a potential valuation re-rating driven by balance sheet improvements and strong asset performance.

Applied Digital Corporation

Applied Digital is experiencing significant volatility as investors weigh the stock's long-term potential in AI infrastructure against broader market pressures, including geopolitical instability and anticipation ahead of upcoming earnings. While some community members are expressing frustration over the recent sharp decline and delayed updates, others are viewing the current price levels as a strategic buying opportunity for long-term positions.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending following the FDA approval of EMPAVELI for rare kidney diseases, a long-awaited catalyst that de-risks the company and strengthens its nephrology portfolio. The community is actively debating the stock's future, balancing optimism over this label expansion and upcoming earnings with lingering frustration regarding management's past execution and previous revenue guidance challenges.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as traders debate the sustainability of recent rallies in the chip sector amidst heightened geopolitical uncertainty and oil market volatility. Community discourse is sharply divided between those positioning for a long-term semiconductor correction and those cautioning against holding structurally decaying inverse ETFs, especially as high-profile announcements from the AI space continue to fuel sentiment shifts.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as investors weigh conflicting signals from the White House regarding potential de-escalation in the Middle East against persistent supply risks and reports of tanker attacks. The community is actively debating whether recent price volatility is driven by genuine geopolitical shifts or algorithmic manipulation, with many traders closely monitoring the Strait of Hormuz for impacts on global crude supply.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point of intense community debate, driven by a mix of long-term sentiment among holders banking on institutional tokenization and a vocal group of traders focused on recent volatility and all-time low price points. Discussions are currently centered on the impact of a newly constituted Board of Directors and the project's pivot toward U.S. operations, with the community split between those accumulating 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update

Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 5,797,071 shares, a decline of 13.8% from the February 26th total of 6,727,046 shares. Based on an average daily trading volume...

Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $2.50 target price on shares of Lucid Diagnostics in a report on Monday...

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results PR...

Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised shares of Lucid Diagnostics from a "sell" rating to a "hold" rating in a research report on Saturday...

Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts...

Needham & Company LLC Reiterates Buy Rating for Lucid Diagnostics (NASDAQ:LUCD)

Needham & Company LLC reissued a "buy" rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research note on Thursday...

Lucid Diagnostics Q4 Earnings Call Highlights

Lucid Diagnostics (NASDAQ:LUCD) reported higher fourth-quarter 2025 EsoGuard testing volume and revenue and highlighted progress on reimbursement initiatives, including a new U.S. Department of Veterans Affairs (VA) contract and ongoing discussions with Medicare and commercial payers.

Fourth-quarte...

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -42.86% and +15.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025...

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth (DRIO) delivered earnings and revenue surprises of +48.88% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Lucid Diagnostics Inc

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

Current Price	$1.17
Prev Close	$1.15
Open	$1.15
Dividend Yield	0.00%
50-Day Moving Average	$1.29
Beta	0.67
Avg. Volume	840,368.34
PE Ratio	-1.40

52-Week High	$1.80
52-Week Low	$0.9495
Market Capitalization	$203.49M
EPS (Annual)	-$0.6922
Price to Book	-3.48
Revenue Per Employee	$57,390.24

LUCD
Lucid Diagnostics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LUCD News

LUCDLucid Diagnostics Inc